How long does it take for resistance to pemetinib to develop?

Pemigatinib is an oral, selective FGFR (fibroblast growth factor receptor) 1, 2 and 3 inhibitors are mainly used to treat cholangiocarcinoma and other related tumors carrying FGFR gene fusion or rearrangement. By blocking the FGFR signaling pathway, pemetinib can inhibit the proliferation and survival of tumor cells and improve patients' clinical symptoms and survival. But like other targeted drugs, drug resistance is a key factor affecting the sustainability of efficacy.

Based on clinical studies and real-world data, the progression-free survival (PFS) of pemetinib is usually 6 to 9 months, and some patients may develop earlier signs of disease progression or resistance. The emergence time of drug resistance varies depending on individual patient differences, tumor genetic characteristics, treatment background, concomitant medication and other factors. In general, most patients may face the risk of drug resistance within about half a year of taking the drug, and the efficacy needs to be closely monitored.

The resistance mechanisms of pemetinib are complex and diverse, mainly including the downstream escape of tumor cells from the FGFR pathway, activation of other signaling pathways, secondary mutations or substitution mutations of the FGFR gene, and changes in the tumor microenvironment. These mechanisms allow tumor cells to bypass drug inhibition and regain their ability to grow and spread, leading to reduced efficacy and disease recurrence.

In the face of resistance to pemetinib, a variety of clinical strategies are often adopted, such as adjusting treatment plans based on genetic testing and trying to combine with other targeted drugs, chemotherapy or immunotherapy; actively participating in clinical trials and using new generation FGFR inhibitors or multi-target drugs; strengthening dynamic monitoring, early identification of resistance signals, and timely adjustment of treatment. Patients should develop an individualized drug resistance management plan under the guidance of professional doctors to extend the duration of efficacy and improve quality of life.

Reference materials:https://www.drugs.com